netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 5: Infections - Full Chapter
05.01.07  Expand sub section  Some other antibacterials
Fosfomycin (Monuril)
View adult BNF View SPC online
Formulary Sachets: 3g 
   
05.01.07  Expand sub section  Chloramphenicol
Chloramphenicol
View adult BNF View SPC online
Formulary Capsules: 250mg 
   
Chloramphenicol
View adult BNF View SPC online
Formulary
Red
Injection (for IV infusion): 1g 
   
05.01.07  Expand sub section  Fusidic acid
Sodium fusidate
View adult BNF View SPC online
Formulary
Green +

Tablets: 250 mg
Oral suspension: 250 mg/5 mL (as fusidic acid)

 
   
Sodium fusidate
View adult BNF View SPC online
Formulary
Red

Vial: powder and solvent for solution for infusion, 500 mg

 

 
   
05.01.07  Expand sub section  Vancomycin and teicoplanin
Teicoplanin
View adult BNF View SPC online
Formulary
Red
Injection (for IV infusion): 200mg, 400mg 
   
Vancomycin
View adult BNF View SPC online
Formulary
Green +
Capsules: 125mg 
   
Vancomycin
View adult BNF View SPC online
Formulary
Red
Injection (for IV infusion): 500mg, 1g 
   
05.01.07  Expand sub section  Daptomycin to top
Daptomycin
View adult BNF View SPC online
Formulary
Red
Injection (for IV infusion): 350mg, 500mg 
   
05.01.07  Expand sub section  Linezolid
Linezolid
View adult BNF View SPC online
Formulary
Green +
Tablets: 600mg
Oral solution: 100mg/5ml 
   
Linezolid
View adult BNF View SPC online
Formulary
Red
IV infusion: 600mg/300ml 
   
05.01.07  Expand sub section  Quinupristin and dalfopristin
05.01.07  Expand sub section  Polymyxins
Colistimethate inhaler (Colobreathe)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Dry powder for inhalation: 1.66 million units per capsule (Colobreathe)

Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy.
 
Link  NHS England Clinical Commissioning Policy
Link  NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
   
Colistimethate sodium
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Injection: 1,000,000 units, 2,000,000 units
Powder for nebulised solution: 1,000,000 units 
   
05.01.07  Expand sub section  Rifaximin
Rifaximin
View adult BNF View SPC online
Formulary
Green +
Tablets: 550mg 
Link  NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
   
05.01.07  Expand sub section  Fidaxomicin to top
Fidaxomicin
View adult BNF View SPC online
Formulary
Green +

Tablets: 200mg

MUST ONLY BE PRESCRIBED ON THE ADVICE OF A MICROBIOLOGIST

See also link above to Risk assessment tool for C Difficile.

 
   
 ....
 Non Formulary Items
Dalbavancin

View adult BNF View SPC online
Non Formulary
 
Oritavancin  (Orbactiv)

View adult BNF View SPC online
Non Formulary
 
Quinupristin and dalfopristin  (Synercid®)

View adult BNF View SPC online
Non Formulary
 
Tedizolid  (Sivextro)

View adult BNF View SPC online
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary